west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "刘剑波" 5 results
  • Effects of dexamethasone on the expression of CCL1 and CCR8 in asthma mice

    Objectives To observe the expression of CCL1/CCR8 mRNA in murine lung tissue of bronchial asthma and effects of glucocorticoids on their expression. Methods Thirthy healthy mice were randomly divided into a control group, an asthma group, and a dexamethasone group, with 10 mice in each group. The sensitized murine asthma model was induced by ovalbumin sensitization and challenge, and the dexamethasone group were peritoneally injected with dexamethasone( 2 mg/ kg) . Total and differential cell counts in BALF were measured. IL-4 Level in BALF was evaluated by ELISA. The expression of CCL1 and CCR8 mRNA in the lungs were measured by semi-quantitative RT-PCR. Results The percentage of eosinophils, lymphocyte and IL-4 level in the asthma group increased significantly compared with the controlgroup, and which in the dexamethasone group decreased significantly compared with the asthma group and still higher than the control group( all P lt; 0. 01) . The expression of CCL1 and CCR8 mRNA had the same tendency ( all P lt;0. 01) . Conclusions The gene expression of CCL1/CCR8 is up-regulated in allergic asthma mice.Glucocorticoids can relieve airway inflammation of asthma probably by inhibiting CCL1/CCR8 expression.

    Release date:2016-08-30 11:52 Export PDF Favorites Scan
  • γ-氨基丁酸A 受体与哮喘关系的研究进展

    Release date:2016-09-13 04:07 Export PDF Favorites Scan
  • The Effect of Medical Ozone on Lung Tissue of Pulmonary Fibrosis Rats

    ObjectiveTo explore the feasibility of medical ozone in treatment of pulmonary fibrosis. MethodsForty Wistar rats were randomly divided into an experimental group and a control group, with 20 rats in each group.All rats were intratreacheally instilled with bleomycin to induce pulmonary fibrosis.Then the rats were intraperitoneally injected with physiological saline every other day in the control group, and with medical ozone every other day in the experimental group.After 28 days, 10 rats in each group were sacrificed after lung function test.Right lung tissues were sampled for pathological examination, and left lung tissues were sampled for measurement of superoxide dismutase (SOD) and hydroxyproline.The remaining 10 rats in each group continued to be normally fed and intraperitoneally injected for observation of the survival time. ResultsThe lung function of the control group significantly decreased compared with the experimental group.The degree of lung fibrosis in the control group was more severe than that in the experimental group (lung fibrosis score: 1.9±0.5 vs.1.2±0.4, P < 0.05). The level of SOD in lung tissue was significantly higher and the level of hydroxyproline was significantly lower in the experimental group compared with the control group [(208.48±29.37)U·mg-1·pro-1 vs.(163.34±21.42) U·mg-1·pro-1, (2.25±0.28) mg/g vs.(2.68±0.37) mg/g, P < 0.05].The rats in the experimental group had longer survival time compared with the control group (79 d vs.59 d, P < 0.05). ConclusionMedical ozone can delay the progress of pulmonary fibrosis in rats.

    Release date: Export PDF Favorites Scan
  • The effect of inhaled glucocorticoid triple therapy on the frequency of acute exacerbations in patients with moderate to severe chronic obstructive pulmonary disease with different blood eosinophil percentage

    Objective To study the effect of glucocorticoid-containing triple therapy on the acute exacerbation frequency of patients with moderate to severe chronic obstructive pulmonary disease (COPD) with different blood eosinophil percentage (EOS%). Methods One hundred and twenty-four patients who were admitted to the hospital with moderate to severe COPD from January 2020 to March 2020 in the Department of Respiratory and Critical Care Medicine in this hospital were selected as the research subjects, and the patients were divided into group A according to EOS% (EOS%<2%) and B group (EOS%≥2%). Then the A and B groups were randomly divided into four subgroups A1, A2 and B1, B2, and the patients in groups A1 and B1 were treated with dual long-acting bronchodilation. The medication for the patients in groups A2 and B2 was a triple preparation containing glucocorticoids. Namely A1 group (EOS%<2%, dual therapy), A2 group (EOS%<2%, triple therapy), B1 group (EOS%≥2%, dual therapy), B2 group (EOS%≥2%, triple therapy). The patients were instructed to take medication regularly as in hospital after discharge. After discharge, patients were followed up by telephone every two weeks for a period of one year. The number of acute exacerbations, the change of forced expiratory volume in the first second as a percentage of the expected value (FEV1%pred) and the incidence of pneumonia were compared between group A and group B during the follow-up period of one year. Results In the patients with EOS%≥2%, triple therapy reduced the number of acute attacks by 40% during treatment compared with dual therapy patients (average 0.875 vs. 1.471 times per patient per year, P=0.0278). While in the patients with EOS%<2%, it was reduced by 4% (1.080 vs. 1.125 times, P=0.3527). In the same use of glucocorticoid-containing triple preparations, the number of acute exacerbations in the patients with EOS%≥2% during medication was 19% less than that of the patients with EOS%<2% (an average of 0.875 to 1.080 times per patient per year, P=0.0462). Regardless of EOS%≥2% or <2%, there was no significant difference in the changes of FEV1%pred between triple therapy and double therapy patients before and after treatment (P>0.05). Regardless of EOS%≥2% or <2%, there was no statistically significant difference in the incidence of pneumonia between patients with triple therapy and double therapy during medication (P>0.05). Conclusion Inhaled glucocorticoid triple therapy is suitable for moderate to severe COPD patients with high percentages of blood eosinophils.

    Release date: Export PDF Favorites Scan
  • A Brief Study on the Quality of Clinical Trials in 11 Medical Journals of Traditional Chinese Medicine From 1995 to 2000

    Objective To identify and investigate the quality of randomized controlled trials (RCTs) of traditional Chinese medicine (TCM) in 11 non-key Chinese medical journals so as to learn about the current status and problems. Methods Eleven non-key medical journals of TCM from 1995 to 2000 were hand searched to identify the RCT and controlled clinical trials (CCTs). Each identified RCT or CCT was page by page verified by handsearchers based on the criteria developed by the Cochrane Handbook; the RCTs’ design, randomization method description, blind, baseline comparison, inclusion and exclusion criteria, diagnostic criteria,criteria for theraputic effectiveness, sample size, statistical method,described outcome, side effects, and follow up etc. were analyzed. Results In the related journals from 1995 to 2000, a total of 66 volumes and 390 issues were checked. As a result, 22 739 clinical studies were identified, of which 1 416 RCTs, only 24 (1.69%) were done with double blinding. There were 141 CCTs from 1995 to 2000, the total number of RCT increased from 95 to 1 416 and most of studies were on digestives diseases. Most of these studies had no detailed randomization method description, only 38 (2.68%) studies provided a methodology description. In addition, 1 220 (86.16% ) described outcome index, 1 203 (84.96%) used statistical method,934 (65.96%) had baseline comparison,828 (58.47%) described diagnostic criteria, 197 (13.91%) had inclusion and exclusion criteria,finally only 89 (6.29%) reported side effects. Conclusions Although the number of RCT has increased in the 11 non-key medical journals of TCM in the past six years, the quality of these RCTs needs to be improved.

    Release date:2016-09-07 02:28 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content